Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | RAF1 | P04049 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.60 |
| ▸ | VCAM1 | P19320 | 15/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
| ▸ | BMP1 | P13497 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7536269 | 0.86 | PKM (0.61) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL809482 | 0.86 | VCAM1 (0.73) | ALDH1A1VCAM1NPBWR1MCHR1 | |
| SCHEMBL29780388 | 0.86 | VCAM1 (0.73) | ALDH1A1VCAM1NPBWR1MCHR1 | |
| SCHEMBL10452716 | 0.86 | VCAM1 (0.73) | ALDH1A1VCAM1NPBWR1MCHR1 | |
| SCHEMBL11456478 | 0.86 | ALPL (0.63) | ALDH1A1LMNARAF1MAPTHPGD | |
| SCHEMBL14553430 | 0.84 | PKM (0.58) | LMNAMAPTMAPK1VCAM1PKM | |
| SCHEMBL12639368 | 0.83 | VCAM1 (0.65) | ALDH1A1MAPK1VCAM1NPBWR1MCHR1 | |
| SCHEMBL541479 | 0.82 | ALDH1A1 (0.68) | ALDH1A1LMNARAF1MAPTHPGD | |
| SCHEMBL6677229 | 0.82 | VCAM1 (0.60) | ALDH1A1LMNARAF1MAPTHPGD | |
| SCHEMBL7533291 | 0.82 | TXNRD1 (0.58) | ALDH1A1LMNARAF1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | ALDH1A1 1173/4885LMNA 2006/4885RAF1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.